385 related articles for article (PubMed ID: 22691895)
1. Treatment of overactive bladder symptoms beyond antimuscarinics: current and future therapies.
Ellsworth P
Postgrad Med; 2012 May; 124(3):16-27. PubMed ID: 22691895
[TBL] [Abstract][Full Text] [Related]
2. Treatment patterns and costs among patients with OAB treated with combination oral therapy, sacral nerve stimulation, percutaneous tibial nerve stimulation, or onabotulinumtoxinA in the United States.
Kraus SR; Shiozawa A; Szabo SM; Qian C; Rogula B; Hairston J
Neurourol Urodyn; 2020 Nov; 39(8):2206-2222. PubMed ID: 32827230
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of novel therapies for overactive bladder.
Mayr CA; Shepherd JP
Expert Rev Pharmacoecon Outcomes Res; 2014 Aug; 14(4):527-35. PubMed ID: 24809616
[TBL] [Abstract][Full Text] [Related]
4. Solabegron: a potential future addition to the β-3 adrenoceptor agonist armamentarium for the management of overactive bladder.
Ellsworth P; Fantasia J
Expert Opin Investig Drugs; 2015 Mar; 24(3):413-9. PubMed ID: 25557359
[TBL] [Abstract][Full Text] [Related]
5. Emerging drugs for overactive bladder.
Karmarkar R; Khullar V
Expert Opin Emerg Drugs; 2015; 20(4):613-24. PubMed ID: 26359223
[TBL] [Abstract][Full Text] [Related]
6. An overview of treatment of overactive bladder syndrome in women.
Allahdin S; Oo N
J Obstet Gynaecol; 2012 Apr; 32(3):217-21. PubMed ID: 22369391
[TBL] [Abstract][Full Text] [Related]
7. [Update on the second line management of idiopathic overactive bladder].
Chartier-Kastler E; Castro-Diaz D; De Ridder D; Everaert K; Sievert KD; Spinelli M; van Kerrebroeck P
Prog Urol; 2009 Sep; 19(8):530-7. PubMed ID: 19699450
[TBL] [Abstract][Full Text] [Related]
8. Update on the treatment of overactive bladder.
Dmochowski RR; Gomelsky A
Curr Opin Urol; 2011 Jul; 21(4):286-90. PubMed ID: 21499104
[TBL] [Abstract][Full Text] [Related]
9. A drug safety evaluation of mirabegron in the management of overactive bladder.
Robinson D; Thiagamoorthy G; Cardozo L
Expert Opin Drug Saf; 2016 May; 15(5):689-96. PubMed ID: 26980445
[TBL] [Abstract][Full Text] [Related]
10. Prospective Pilot Study of Mirabegron in Pediatric Patients with Overactive Bladder.
Blais AS; Nadeau G; Moore K; Genois L; Bolduc S
Eur Urol; 2016 Jul; 70(1):9-13. PubMed ID: 26876327
[TBL] [Abstract][Full Text] [Related]
11. Overactive bladder syndrome - management and treatment options.
Arnold J; McLeod N; Thani-Gasalam R; Rashid P
Aust Fam Physician; 2012 Nov; 41(11):878-83. PubMed ID: 23145420
[TBL] [Abstract][Full Text] [Related]
12. The management of overactive bladder: percutaneous tibial nerve stimulation, sacral nerve stimulation, or botulinum toxin?
Tubaro A; Puccini F; De Nunzio C
Curr Opin Urol; 2015 Jul; 25(4):305-10. PubMed ID: 26049873
[TBL] [Abstract][Full Text] [Related]
13. New evidence in the treatment of overactive bladder.
Brown ET; Martin L; Dmochowski RR
Curr Opin Obstet Gynecol; 2015 Oct; 27(5):366-72. PubMed ID: 26308197
[TBL] [Abstract][Full Text] [Related]
14. Mirabegron for overactive bladder syndrome.
Drug Ther Bull; 2013 Aug; 51(8):90-2. PubMed ID: 23949821
[TBL] [Abstract][Full Text] [Related]
15. Overactive Bladder and the β3-Adrenoceptor Agonists: Current Strategy and Future Prospects.
Giarenis I; Robinson D; Cardozo L
Drugs; 2015 Oct; 75(15):1707-13. PubMed ID: 26323339
[TBL] [Abstract][Full Text] [Related]
16. Actual treatment of overactive bladder and urge urinary incontinence.
Cornu JN
Minerva Urol Nefrol; 2013 Mar; 65(1):21-35. PubMed ID: 23538308
[TBL] [Abstract][Full Text] [Related]
17. Understanding clinic options for overactive bladder.
Bartley JM; Blum ES; Sirls LT; Peters KM
Curr Urol Rep; 2013 Dec; 14(6):541-8. PubMed ID: 23812967
[TBL] [Abstract][Full Text] [Related]
18. New therapies in the treatment of overactive bladder.
Yeo EK; Hashim H; Abrams P
Expert Opin Emerg Drugs; 2013 Sep; 18(3):319-37. PubMed ID: 23885696
[TBL] [Abstract][Full Text] [Related]
19. [Developments in the medical treatment of overactive bladder].
Alcántara Montero A
Semergen; 2016; 42(8):557-565. PubMed ID: 26671329
[TBL] [Abstract][Full Text] [Related]
20. Management of refractory OAB in the non-neurogenic patient.
Wadie BS
Curr Urol Rep; 2014 Sep; 15(9):438. PubMed ID: 25015301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
